10-Q: Delcath Systems Reports Strong Q2 Growth

Delcath Systems, Inc. reported a significant increase in product revenue and a shift to net income for the six months ended June 30, 2025, driven by the commercial expansion of HEPZATO KIT and CHEMOSAT.

Summary

• Product revenue for the six months ended June 30, 2025, surged to $43.9 million, a substantial increase from $10.9 million in the same period of 2024.
• The company achieved a gross profit of $37.8 million for the first half of 2025, up from $8.5 million in the prior year.
• Net income for the six months ended June 30, 2025, was $3.8 million, a significant improvement from a net loss of $24.9 million in the corresponding period of 2024.
• Cash provided by operating activities was $9.5 million for the six months ended June 30, 2025, a positive reversal from $14.0 million used in the prior year.
• HEPZATO KIT sales were the primary driver of revenue growth, increasing from $8.6 million in H1 2024 to $40.5 million in H1 2025.
• CHEMOSAT sales also increased to $3.4 million in H1 2025 from $2.3 million in H1 2024.
• 20 facilities had treated at least one patient with HEPZATO in H1 2025, compared to 7 facilities in H1 2024.
• Research and development expenses increased to $11.9 million in H1 2025 from $7.1 million in H1 2024, primarily due to clinical team expansion and initiation of Phase 2 trials.
• Selling, general, and administrative expenses rose to $22.7 million in H1 2025 from $15.6 million in H1 2024, driven by commercial expansion and increased personnel.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth and a shift to profitability and positive operating cash flow. Expansion into new clinical trials for additional indications shows strategic growth. While R&D and SG&A expenses are increasing, they are tied to commercialization and pipeline development. Regulatory risks are noted but are common in the industry. The overall outlook is positive due to commercial traction and pipeline progression.

Positives

• Significant increase in product revenue, reaching $43.9 million for the six months ended June 30, 2025, compared to $10.9 million in the prior year.
• Achieved net income of $3.8 million for the six months ended June 30, 2025, a substantial improvement from a net loss of $24.9 million in the same period of 2024.
• Positive cash flow from operating activities of $9.5 million for the first half of 2025, reversing a $14.0 million cash usage in the prior year.
• Strong commercial expansion of HEPZATO KIT in the United States, with 20 facilities treating patients in H1 2025, up from 7 in H1 2024.
• Increased cash and cash equivalents to $34.4 million and short-term investments to $46.6 million as of June 30, 2025, indicating improved liquidity.
• Clearance of IND applications by the FDA for Phase 2 clinical trials of HEPZATO in liver-dominant metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC), expanding potential indications.
• Authorization from EU and UK regulatory authorities for the clinical study of Melphalan for Injection/Hepatic Delivery System in refractory metastatic colorectal cancer.
• CHEMOSAT approved for reimbursement for two years in the Vastra Gotaland Region in Sweden in June 2025.
• All debt paid off in 2024, eliminating interest expense in H1 2025.

Negatives

• Increased research and development expenses to $11.9 million for H1 2025, driven by clinical trial expansion, which will continue to rise.
• Higher selling, general, and administrative expenses of $22.7 million for H1 2025 due to commercial expansion activities and increased personnel.
• Subject to potential penalties for failing to make timely and/or accurate reports of required values under the National Drug Rebate Agreement (NDRA), Pharmaceutical Pricing Agreement (PPA), and VA agreement.
• The Medicare Drug Price Negotiation Program and other healthcare cost-containment initiatives could negatively impact future revenue and profitability.
• Uncertainty regarding the full effect of the One Big Beautiful Bill (OBBB) on future tax provisions, despite potential benefits like R&D expensing.

Risks

• Risks associated with developing product candidates and successfully launching and commercializing drug/device combination products.
• Ability to obtain regulatory approval of products in the United States and other geographic markets.
• Uncertainty of broad adoption of approved products by physicians and consumers.
• Significant competition in the biopharmaceutical industry.
• Economic uncertainty due to high inflation and increased interest rates, potentially affecting access to capital.
• Threat to access existing cash, cash equivalents, and investments if additional banks and financial institutions become insolvent.
• Difficulties and delays in manufacturing products due to geopolitical events, global health outbreaks, adverse weather, labor/raw material shortages, tariffs, or supply chain disruptions.
• Potential for inventory write-offs and other charges for products failing to meet specifications or requiring costly remediation.
• Risk of losing revenue or market share if patients and physicians turn to competing therapeutics.
• Failure to comply with reporting and payment obligations under Medicaid Drug Rebate Program or other governmental pricing programs could lead to penalties, sanctions, and fines.
• Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, could significantly impact the business.
• The Inflation Reduction Act of 2022 (IRA) provisions, such as Medicare price negotiations and inflation-based rebates, could negatively affect revenue.
• The overturning of the Chevron doctrine by the U.S. Supreme Court (Loper Bright decision) could result in additional legal challenges to current regulations and guidance from federal agencies like the FDA.
• Changes in tax laws or regulations, including the One Big Beautiful Bill (OBBB), could adversely affect business operations and financial performance.

Future Outlook

The company expects research and development expenses to increase for the foreseeable future due to ongoing Phase 2 clinical trials for liver-dominant metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC). Patient enrollment for the mCRC trial is expected to begin in the second half of 2025, with hepatic progression-free survival (hPFS) data anticipated by the end of 2027 and overall survival (OS) expected in 2028. For the mBC trial, patient enrollment is expected to begin in the fourth quarter of 2025, with hPFS data anticipated by the end of 2028 and OS in 2029. The company believes HEPZATO has the potential to treat other liver cancers, representing significant market opportunities, with estimated annual addressable markets of 6,000-10,000 mCRC patients and approximately 7,000 HER2-negative mBC patients in the United States.

Management Comments

• We have sufficient raw material and component constituent parts of the HEPZATO KIT to meet anticipated demand and it intends to manage supply chain risk through stockpiled inventory and, where commercially reasonable, contracting with multiple suppliers for critical components.
• We believe that our current cash on hand, cash equivalents and investments will be sufficient to support our current operations through at least 12 months from the issuance of these consolidated financial statements.

Industry Context

Delcath Systems operates in the interventional oncology space, a specialized and growing field focused on liver-directed cancer treatments. The significant revenue growth, particularly from HEPZATO KIT, indicates successful commercialization post-FDA approval, positioning the company to capture market share in niche indications like uveal melanoma. The expansion into mCRC and mBC clinical trials aligns with a broader industry trend of developing targeted therapies for liver metastases, which represent substantial unmet medical needs and large market opportunities. The company's focus on combination therapies (e.g., HEPZATO with SOC/immunotherapy) reflects a common strategy in oncology to improve treatment efficacy and patient outcomes. Regulatory changes, such as the Inflation Reduction Act and the recent One Big Beautiful Bill, highlight the increasing scrutiny on drug pricing and R&D incentives, which are critical factors for biopharmaceutical companies.

Comparison to Industry Standards

• The reported Overall Response Rate (ORR) of 36.3% for HEPZATO in the FOCUS trial for metastatic uveal melanoma (mUM) is statistically significantly better than the pooled ORR estimate of 5.5% in the historical control group, indicating strong clinical efficacy for its approved indication.
• The estimated total addressable market (TAM) for liver-dominant mCRC receiving third-line treatment (6,000-10,000 patients annually in the US) and HER2-negative mBC with liver metastases (approximately 7,000 patients annually in the US) suggests substantial market opportunities for HEPZATO, comparable to other niche oncology indications that have supported successful product launches.
• The shift from significant cash usage in operating activities ($14.0 million used in H1 2024) to positive cash generation ($9.5 million provided in H1 2025) demonstrates a strong operational turnaround, which is a positive indicator compared to many early-commercialization stage biopharmaceutical companies that often remain cash-flow negative for longer periods.
• The company's ability to pay off all debt in 2024 and generate interest income in H1 2025, while increasing cash and investments, suggests a stronger financial position than many peers in the development or early commercialization phase, who often rely on continuous capital raises.

Legal Proceedings

• The company reached a final settlement with medac GmbH on December 30, 2022, regarding a dispute over a 1 million milestone payment.
• The company agreed to pay medac either a royalty on CHEMOSAT sales over a defined minimum for five years or until a maximum payment is reached, or a minimum annual payment of $0.2 million if royalties don't meet the minimum.
• The remaining fair value of the settlement is estimated to be $0.8 million as of June 30, 2025, with $0.6 million as non-current and $0.2 million as accrued expenses.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, shift to profitability, and positive operating cash flow, potentially leading to increased shareholder value. The company's improved liquidity and strategic pipeline expansion could enhance long-term prospects.
• Patients: Potential for new treatment options for liver-dominant metastatic colorectal cancer and metastatic breast cancer through ongoing Phase 2 clinical trials, addressing unmet medical needs. Continued access to HEPZATO for uveal melanoma.
• Employees: Increased headcount in clinical and commercial teams, indicating growth and potential for more employment opportunities. Stock-based compensation plans (2020 Plan, 2023 Inducement Plan, ESPP) provide incentives.
• Hospitals/Treatment Centers: Increased adoption and use of HEPZATO KIT, with 20 facilities treating patients in H1 2025, indicating growing clinical utility and demand.
• Suppliers: Continued demand for raw materials and components for HEPZATO KIT, with the company managing supply chain risk through stockpiled inventory and multiple suppliers.
• Regulatory Authorities: Ongoing compliance with FDA regulations for HEPZATO and European MDR certification for CHEMOSAT. New obligations under NDRA, PPA, and VA agreements require careful pricing calculations and reporting.

Next Steps

• Patient enrollment for the Phase 2 clinical trial evaluating HEPZATO in liver-dominant metastatic colorectal cancer (mCRC) is expected to begin in the second half of 2025.
• Hepatic progression-free survival (hPFS) data for the mCRC trial is anticipated to read out by the end of 2027, with overall survival (OS) expected in 2028.
• Patient enrollment for the Phase 2 clinical trial of HEPZATO in liver-dominant HER2-negative metastatic breast cancer (mBC) is expected to begin in the fourth quarter of 2025.
• Hepatic progression-free survival (hPFS) data for the mBC trial is anticipated to read out by the end of 2028, with overall survival (OS) expected in 2029.
• The company will continue to evaluate the effect of the One Big Beautiful Bill (OBBB) on its future interim and annual financial statements.
• The company is obligated to make sales to the VA at the Federal Ceiling Price starting July 1, 2025.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance, marked by a substantial increase in product revenue and a significant turnaround from a net loss to profitability. The shift to positive cash flow from operations is a critical indicator of sustainable growth and reduced reliance on external financing. The successful commercialization of HEPZATO KIT, evidenced by the growing number of treating facilities, validates its market acceptance. Furthermore, the strategic expansion into large addressable markets like metastatic colorectal cancer and metastatic breast cancer through ongoing Phase 2 clinical trials presents significant long-term growth opportunities. While R&D and SG&A expenses are increasing, they are directly tied to pipeline development and commercial scale-up, which are necessary investments for future revenue streams. The improved liquidity position and the absence of debt further strengthen the company's financial health. Given the strong operational performance, expanding market reach, and promising pipeline, the stock presents a compelling 'strong buy' opportunity for investors seeking growth in the interventional oncology sector.

Keywords

Delcath Systems, HEPZATO KIT, CHEMOSAT, Uveal Melanoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Interventional Oncology, Drug-Device Combination, FDA Approval, Clinical Trials, Biopharmaceutical, Orphan Drug, Financial Results, SEC Filing, Healthcare, Oncology